Annual report pursuant to Section 13 and 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

v3.10.0.1
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($)
$ in Thousands
Common Stock [Member]
Additional Paid-in Capital [Member]
Receipts on Account of Share to be Allotted [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Equity Attributable to Orgenesis Inc. [Member]
Non-Controlling Interest [Member]
Total
Beginning Balance at Nov. 30, 2016 $ 1 $ 45,454   $ (1,205) $ (31,753) $ 12,497   $ 12,497
Beginning Balance (Shares) at Nov. 30, 2016 9,508,068              
Stock-based compensation to employees and directors   1,536       1,536   1,536
Stock-based compensation to service providers   1,828       1,828   1,828
Stock-based compensation to service providers (Shares) 79,167              
Issuance of shares and receipts on account of shares and warrants to be allotted   3,702 $ 1,483     5,185   5,185
Issuance of shares and receipts on account of shares and warrants to be allotted (Shares) 285,424              
Beneficial conversion feature of convertible loans and Warrants issued   2,814       2,814   2,814
Adjustment to redemption value of redeemable non-controlling interest               0
Comprehensive income (loss) for the period       2,630 (12,367) (9,737)   (9,737)
Ending Balance at Nov. 30, 2017 $ 1 55,334 1,483 1,425 (44,120) 14,123   14,123
Ending Balance (Shares) at Nov. 30, 2017 9,872,659              
Stock-based compensation to employees and directors   2,426       2,426   2,426
Stock-based compensation to service providers   1,938       1,938   1,938
Stock-based compensation to service providers (Shares) 315,198              
Issuance of shares and warrant due to conversion of convertible loans   7,511       7,511   7,511
Issuance of shares and warrant due to conversion of convertible loans (Shares) 1,486,722              
Issuance of warrants and beneficial conversion feature of convertible loans   438       438   438
Issuance of shares and receipts on account of shares to be allotted related to acquisition of Atvio and CureCell   2,452       2,452 $ 299 2,751
Issuance of shares and receipts on account of shares to be allotted related to acquisition of Atvio and CureCell (Shares) 286,811              
Issuance of shares and receipts on account of shares and warrants to be allotted   18,021 770     18,791   18,791
Issuance of shares and receipts on account of shares and warrants to be allotted (Shares) 2,853,747              
Issuance of Shares due to exercise of warrants   846       846   846
Issuance of Shares due to exercise of warrants (Shares) 136,646              
Adjustment to redemption value of redeemable non-controlling interest   (884)       (884)   (884)
Comprehensive income (loss) for the period       (1,000) (18,291) (19,291)   (19,291)
Ending Balance at Nov. 30, 2018 $ 1 $ 88,082 $ 2,253 $ 425 $ (62,411) $ 28,350 $ 299 $ 28,649
Ending Balance (Shares) at Nov. 30, 2018 14,951,783